Wednesday, October 7, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· March 5, 2026

Chronic Rhinosinusitis with Nasal Polyps Market Shows Strong Upward Momentum During the Forecast Period (2026-2036) as Demand for Advanced Therapies Rises | DelveInsight

View original at finance.yahoo.com
Chronic Rhinosinusitis with Nasal Polyps Market Shows Strong Upward Momentum During the Forecast Period (2026-2036) as Demand for Advanced Therapies Rises | DelveInsight The chronic rhinosinusitis with nasal polyps market growth is being driven by rising disease prevalence, greater awareness, and improved diagnostic ra…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The dynamics of the CRSwNP market are expected to change in the coming years due to the launch of emerging therapies such as Depemokimab, Verekitug (UPB-101), Lunsekimig, LY3650150, and others

    80% confidence

  • Treatment strategies are shifting beyond conventional intranasal corticosteroids, systemic steroids, and surgery toward targeted biologic therapies, enabling more personalized and sustained disease control for patients

    80% confidence

  • Gender distribution of CRSwNP in the US shows male predominance with 55% of diagnosed prevalent cases being males

    80% confidence

  • The 7MM accounted for 4.5 million diagnosed prevalent cases of CRSwNP in 2025, which are expected to increase during the study period

    80% confidence

  • GSK has expressed continued confidence in depemokimab's potential for CRSwNP and is maintaining discussions with the FDA

    80% confidence

  • The total chronic rhinosinusitis with nasal polyps treatment market size is expected to grow positively by 2036 in the leading markets

    80% confidence

  • CRSwNP is expected to see a rising disease burden over the forecast period (2026-2036), driven primarily by increasing prevalence, improved diagnosis, and evolving treatment approaches

    80% confidence

  • The United States accounted for the largest CRSwNP treatment market size in 2025, compared to other major markets

    80% confidence

  • The US had around 2 million diagnosed prevalent cases of CRSwNP in 2025

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,362 source documents archived
Query this data → isubstrate.com
Chronic Rhinosinusitis with Nasal Polyps Market Shows Strong Upward Momentum During the Forecast Period (2026-2036) as Demand for Advanced Therapies Rises | DelveInsight — Source | Via News | ViaNews Market